Listen "Working together in the management of thyroid cancer: An oncologist and endocrinologist in conversation"
Episode Synopsis
In today’s episode, we welcome expert Oncologist Dr. Claire Arthur and expert Endocrinologist Dr. Sarimar Agosto Salgado to discuss the challenges they have encountered and strategies that they have implemented to improve multidisciplinary collaboration in the management of patients with thyroid cancer and continued integration of precision medicine approaches.
References
1. Fenton ME et al. Variability in thyroid cancer multidisciplinary team meeting recommendations is not explained by standard variables: Outcomes of a single centre review. J Clin Med 2021;10:4150
2. Horgan D et al. Tackling thyroid cancer in Europe—The challenges and opportunities. Healthcare 2022;10:1621
3. Mehra S et al. Improving the quality of thyroid cancer care: How does the Thyroid Cancer Care Collaborative cross the Institute of Medicine’s Quality Chasm? Thyroid 2014;24:615–624
Target Audience:
Oncologists, pathologists and other HCPs involved in the diagnosis of RET and TRK cancers, with a focus on community practitioners.
Learning Objective:
1. Recall thyroid RET andTRK fusion-positive cancer diagnosis and relevant genomic testing guidelines and identify ways to adapt the guidelines to local settings
2. Discuss “precision medicine” and new technologies, including “liquid biopsy”
3. Review the organisation of care and strategies for more efficient care delivery
Funding Information:
This episode is supported by an educational grant from Eli Lilly, who have had no influence on the content or choice of faculty.
Disclosures:
Dr Sarimar Agosto Salgado:
- Speaker: Lilly
- Advisor: Exelisis, Lilly, Blueprint medicines, Eisai
Dr Claire Arthur
Dr Claire Arthur has no relevant disclosures against this module
Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
References
1. Fenton ME et al. Variability in thyroid cancer multidisciplinary team meeting recommendations is not explained by standard variables: Outcomes of a single centre review. J Clin Med 2021;10:4150
2. Horgan D et al. Tackling thyroid cancer in Europe—The challenges and opportunities. Healthcare 2022;10:1621
3. Mehra S et al. Improving the quality of thyroid cancer care: How does the Thyroid Cancer Care Collaborative cross the Institute of Medicine’s Quality Chasm? Thyroid 2014;24:615–624
Target Audience:
Oncologists, pathologists and other HCPs involved in the diagnosis of RET and TRK cancers, with a focus on community practitioners.
Learning Objective:
1. Recall thyroid RET andTRK fusion-positive cancer diagnosis and relevant genomic testing guidelines and identify ways to adapt the guidelines to local settings
2. Discuss “precision medicine” and new technologies, including “liquid biopsy”
3. Review the organisation of care and strategies for more efficient care delivery
Funding Information:
This episode is supported by an educational grant from Eli Lilly, who have had no influence on the content or choice of faculty.
Disclosures:
Dr Sarimar Agosto Salgado:
- Speaker: Lilly
- Advisor: Exelisis, Lilly, Blueprint medicines, Eisai
Dr Claire Arthur
Dr Claire Arthur has no relevant disclosures against this module
Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
More episodes of the podcast Oncology Knowledge into Practice Podcast
The ESMO 2022 Clinical Practice Guidelines for use of systemic therapy in advanced thyroid care
21/03/2023
Working together in the management of thyroid cancer: An oncologist and pathologist in conversation
23/09/2022
Tissue is Never the Issue
27/06/2022
Thyroid cancer: testing for biomarkers
01/04/2022
ZARZA We are Zarza, the prestigious firm behind major projects in information technology.